SHUTTLE PHARMACEUTICALS HOLDINGS, INC. Marketable Securities, Gain (Loss), Excluding Other-than-temporary Impairment Loss
SHUTTLE PHARMACEUTICALS HOLDINGS, INC. (SHPH) reported Marketable Securities, Gain (Loss), Excluding Other-than-temporary Impairment Loss of -$42.90 thousand for the 3-month period ending 2024-09-30, per its 10-Q filed 2024-11-13.
Financial Statements › Income Statement › Other Income
us-gaap:MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments · last filed 2025-11-13
- SHUTTLE PHARMACEUTICALS HOLDINGS, INC. marketable securities, gain (loss), excluding other-than-temporary impairment loss for the quarter ending 2024-09-30 was -$42.90K, a 546.58% decline year-over-year.
- SHUTTLE PHARMACEUTICALS HOLDINGS, INC. marketable securities, gain (loss), excluding other-than-temporary impairment loss for the quarter ending 2024-06-30 was -$27.96K.
- SHUTTLE PHARMACEUTICALS HOLDINGS, INC. marketable securities, gain (loss), excluding other-than-temporary impairment loss for the quarter ending 2024-03-31 was -$706.00, a 101.85% decline year-over-year.
- SHUTTLE PHARMACEUTICALS HOLDINGS, INC. marketable securities, gain (loss), excluding other-than-temporary impairment loss for the quarter ending 2023-12-31 was $50.43K.
- SHUTTLE PHARMACEUTICALS HOLDINGS, INC. marketable securities, gain (loss), excluding other-than-temporary impairment loss for fiscal 2023 was $71.57K.
| Period end | Marketable Securities, Gain (Loss), Excluding Other-than-temporary Impairment Loss 3 month | Marketable Securities, Gain (Loss), Excluding Other-than-temporary Impairment Loss 6 month | Marketable Securities, Gain (Loss), Excluding Other-than-temporary Impairment Loss 9 month | Marketable Securities, Gain (Loss), Excluding Other-than-temporary Impairment Loss 12 month |
|---|---|---|---|---|
| 2024-09-30 | -$42.90K 10-Q · filed 2024-11-13 | -$70.86K derived: sum of 2 quarters · filed 2024-11-13 | -$71.57K 10-Q · filed 2025-11-13 | -$21.13K derived: sum of 4 quarters · filed 2025-05-08 |
| 2024-06-30 | -$27.96K 10-Q · filed 2024-09-04 | -$28.67K 10-Q · filed 2025-08-13 | $21.76K derived: sum of 3 quarters · filed 2025-05-08 | $31.37K derived: sum of 4 quarters · filed 2025-05-08 |
| 2024-03-31 | -$706.00 10-Q · filed 2025-05-08 | $49.73K derived: sum of 2 quarters · filed 2025-05-08 | $59.33K derived: sum of 3 quarters · filed 2025-05-08 | $32.80K derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | $50.43K derived: 10-K/A 12 month − 10-Q 9 month · filed 2024-09-04 | $60.04K derived: sum of 2 quarters · filed 2024-11-13 | $33.51K derived: sum of 3 quarters · filed 2024-11-13 | $71.57K 10-K/A · filed 2024-09-04 |
| 2023-09-30 | $9.61K 10-Q · filed 2024-11-13 | -$16.93K derived: sum of 2 quarters · filed 2024-11-13 | $21.13K 10-Q · filed 2024-11-13 | |
| 2023-06-30 | -$26.53K 10-Q · filed 2024-09-04 | $11.53K 10-Q · filed 2024-09-04 | ||
| 2023-03-31 | $38.06K 10-Q/A · filed 2024-09-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Rocket One Inc. (RKTO) | United States | $0.019B | |
| Cellectar Biosciences, Inc. (CLRB) | United States | $0.020B | -1.03 |
| Marker Therapeutics, Inc. (MRKR) | United States | $0.020B | -2.86 |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |
| Biofrontera Inc. (BFRI) | United States | $0.018B | -2.13 |
| Lipocine Inc. (LPCN) | United States | $0.017B | -1.79 |
| PALATIN TECHNOLOGIES INC (PTN) | United States | $0.017B | -5.36 |
| Allarity Therapeutics, Inc. (ALLR) | United States | $0.017B | -1.66 |
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| Pasithea Therapeutics Corp. (KTTA) | United States | $0.017B | -0.81 |